AquaBounty Technologies, Inc.
NASDAQ Capital MarketRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- AquaBounty Technologies, Inc. is a biotechnology company focused on enhancing aquaculture productivity through genetic engineering and land-based fish farming technologies. Founded in 1991 and headquartered in Harvard, Massachusetts, the company develops and commercializes genetically modified aquatic species, including its flagship AquAdvantage Salmon, a sterile female Atlantic salmon engineered with a Chinook salmon growth hormone gene to reach market size in approximately half the time of conventional salmon; conventional Atlantic salmon eggs, fry, and byproducts; and research-stage hybrid trout and tilapia designed for faster growth. It conducts genetic, genomic, fish health, and nutrition research to support sustainable seafood production for fish farmers and consumers in the United States and Canada. In recent developments, the company sold its operating farms in Indiana, Ohio, and Prince Edward Island, including the trademarks and patents for AquAdvantage Salmon, between 2024 and March 2025 to address liquidity challenges amid escalating construction costs for a planned large-scale facility in Pioneer, Ohio; secured short-term financing including a $10 million bridge loan in April 2024 (repaid July 2024), a $4 million senior note issuance in October 2025, and ongoing equipment asset sales totaling $7.1 million in 2025; underwent leadership changes with David F. Melbourne Jr. as President and CEO in June 2024 followed by his resignation in December 2024 and David A. Frank as Interim CEO; and ceased fish production operations while pursuing strategic alternatives for remaining assets.
AquaBounty Technologies, Inc. (NASDAQ:AQB) Sees Significant Decline in Short Interest
AquaBounty Technologies (NASDAQ:AQB) versus Tyra Biosciences (NASDAQ:TYRA) Head to Head Analysis
AquaBounty Technologies, Inc. (NASDAQ:AQB) Short Interest Update
AquaBounty Technologies Announces Third Quarter 2025 Financial Results
AquaBounty Technologies Announces Second Quarter 2025 Financial Results
AquaBounty Technologies Announces First Quarter 2025 Financial Results
AquaBounty Technologies Announces Full Year 2024 Financial Results
AquaBounty Announces Plans to Cease Fish Farming Operations
AquaBounty Technologies, Inc. (AQB) Reports Q3 Loss, Misses Revenue Estimates
AquaBounty Technologies Announces Third Quarter 2024 Financial Results
AquaBounty Technologies Provides Update
AquaBounty Technologies, Inc. (AQB) Reports Q2 Loss, Tops Revenue Estimates
AquaBounty Technologies Announces Second Quarter 2024 Financial Results
David F. Melbourne Jr. Promoted to Chief Executive Officer of AquaBounty; Sylvia Wulf to Continue as Non-Executive Board Chair
AquaBounty Technologies, Inc. (AQB) Reports Q1 Loss, Misses Revenue Estimates
AquaBounty Technologies Announces First Quarter 2024 Financial Results
AquaBounty Technologies Announces Fourth Quarter and Full Year 2023 Financial Results
AquaBounty Technologies Provides Fundraising Update
AquaBounty Technologies Announces Third Quarter 2023 Financial Results
AquaBounty Technologies Announces Reverse Stock Split